14 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Gastrointestinal Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Drug: XELOX regimen;   Drug: hydroxychloroquine
2 Recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Condition: Colorectal Cancer
Interventions: Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
3 Recruiting PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions: Drug: FOLFOX regimen;   Drug: carboplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: paclitaxel
4 Not yet recruiting Internet-Based Weight-Loss Program for Colorectal Cancer Survivors
Conditions: Cancer Survivor;   Colorectal Cancer;   Weight Changes
Intervention: Behavioral: Internet weight loss intervention
5 Recruiting A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Condition: Resectable Pancreatic Cancer
Intervention: Drug: LDE-225
6 Recruiting Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
7 Recruiting Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo
8 Recruiting Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Conditions: Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C/NEO-102
9 Recruiting A Study of DKN-01 in Combination With Paclitaxel
Conditions: Esophageal Neoplasms;   Adenocarcinoma of the Gastroesophageal Junction;   Gastroesophageal Cancer
Interventions: Drug: DKN-01;   Drug: Paclitaxel
10 Recruiting A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Condition: Anal Cancer
Intervention: Biological: Advaxis
11 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Recruiting Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
13 Recruiting A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Condition: Pancreatic Cancer, Adult
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: NPC-1C
14 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: CC-122 HCL

Indicates status has not been verified in more than two years